Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)
$ in Millions |
3 Months Ended |
6 Months Ended |
Jun. 29, 2025 |
Jun. 30, 2024 |
Jun. 29, 2025 |
Jun. 30, 2024 |
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 23,743
|
$ 22,447
|
$ 45,636
|
$ 43,830
|
| Percent Change (as a percent) |
5.80%
|
|
4.10%
|
|
| U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 13,544
|
12,569
|
$ 25,849
|
24,189
|
| Percent Change (as a percent) |
7.80%
|
|
6.90%
|
|
| International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 10,199
|
9,878
|
$ 19,787
|
19,641
|
| Percent Change (as a percent) |
3.20%
|
|
0.70%
|
|
| Innovative Medicine |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 15,202
|
14,490
|
$ 29,075
|
28,052
|
| Percent Change (as a percent) |
4.90%
|
|
3.60%
|
|
| Innovative Medicine | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 9,161
|
8,510
|
$ 17,253
|
16,122
|
| Percent Change (as a percent) |
7.60%
|
|
7.00%
|
|
| Innovative Medicine | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 6,041
|
5,980
|
$ 11,822
|
11,930
|
| Percent Change (as a percent) |
1.00%
|
|
(0.90%)
|
|
| Innovative Medicine | Oncology |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 6,312
|
5,090
|
$ 11,990
|
9,904
|
| Percent Change (as a percent) |
24.00%
|
|
21.10%
|
|
| Innovative Medicine | Oncology | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 3,385
|
2,636
|
$ 6,398
|
5,019
|
| Percent Change (as a percent) |
28.40%
|
|
27.50%
|
|
| Innovative Medicine | Oncology | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 2,928
|
2,455
|
$ 5,592
|
4,885
|
| Percent Change (as a percent) |
19.30%
|
|
14.50%
|
|
| Innovative Medicine | Oncology | CARVYKTI |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 439
|
186
|
$ 808
|
343
|
| Innovative Medicine | Oncology | CARVYKTI | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
358
|
167
|
676
|
307
|
| Innovative Medicine | Oncology | CARVYKTI | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
81
|
20
|
132
|
36
|
| Innovative Medicine | Oncology | DARZALEX |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 3,539
|
2,878
|
$ 6,776
|
5,570
|
| Percent Change (as a percent) |
23.00%
|
|
21.70%
|
|
| Innovative Medicine | Oncology | DARZALEX | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 2,017
|
1,641
|
$ 3,846
|
3,105
|
| Percent Change (as a percent) |
23.00%
|
|
23.90%
|
|
| Innovative Medicine | Oncology | DARZALEX | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,521
|
1,237
|
$ 2,930
|
2,465
|
| Percent Change (as a percent) |
23.00%
|
|
18.90%
|
|
| Innovative Medicine | Oncology | ERLEADA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 908
|
736
|
$ 1,679
|
1,425
|
| Percent Change (as a percent) |
23.40%
|
|
17.80%
|
|
| Innovative Medicine | Oncology | ERLEADA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 378
|
318
|
$ 670
|
603
|
| Percent Change (as a percent) |
18.60%
|
|
11.00%
|
|
| Innovative Medicine | Oncology | ERLEADA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 530
|
418
|
$ 1,009
|
822
|
| Percent Change (as a percent) |
27.00%
|
|
22.90%
|
|
| Innovative Medicine | Oncology | IMBRUVICA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 735
|
770
|
$ 1,444
|
1,554
|
| Percent Change (as a percent) |
(4.50%)
|
|
(7.00%)
|
|
| Innovative Medicine | Oncology | IMBRUVICA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 239
|
246
|
$ 474
|
511
|
| Percent Change (as a percent) |
(2.70%)
|
|
(7.30%)
|
|
| Innovative Medicine | Oncology | IMBRUVICA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 496
|
525
|
$ 970
|
1,043
|
| Percent Change (as a percent) |
(5.40%)
|
|
(6.90%)
|
|
| Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 179
|
69
|
$ 320
|
116
|
| Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
139
|
52
|
252
|
88
|
| Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
41
|
17
|
69
|
28
|
| Innovative Medicine | Oncology | TALVEY |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 106
|
69
|
$ 192
|
127
|
| Percent Change (as a percent) |
55.00%
|
|
52.00%
|
|
| Innovative Medicine | Oncology | TALVEY | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 82
|
59
|
$ 150
|
109
|
| Percent Change (as a percent) |
38.00%
|
|
36.70%
|
|
| Innovative Medicine | Oncology | TALVEY | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 24
|
9
|
$ 42
|
17
|
| Innovative Medicine | Oncology | Tecvayli |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 166
|
135
|
$ 317
|
268
|
| Percent Change (as a percent) |
23.10%
|
|
18.20%
|
|
| Innovative Medicine | Oncology | Tecvayli | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 114
|
104
|
$ 219
|
205
|
| Percent Change (as a percent) |
8.20%
|
|
6.60%
|
|
| Innovative Medicine | Oncology | Tecvayli | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 52
|
30
|
$ 98
|
63
|
| Percent Change (as a percent) |
74.80%
|
|
56.00%
|
|
| Innovative Medicine | Oncology | ZYTIGA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 145
|
165
|
$ 270
|
346
|
| Percent Change (as a percent) |
(11.60%)
|
|
(21.70%)
|
|
| Innovative Medicine | Oncology | ZYTIGA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 6
|
11
|
$ 13
|
20
|
| Percent Change (as a percent) |
(38.90%)
|
|
(31.90%)
|
|
| Innovative Medicine | Oncology | ZYTIGA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 139
|
154
|
$ 257
|
326
|
| Percent Change (as a percent) |
(9.80%)
|
|
(21.10%)
|
|
| Innovative Medicine | Oncology | Other Oncology |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 93
|
83
|
$ 182
|
156
|
| Percent Change (as a percent) |
11.70%
|
|
16.40%
|
|
| Innovative Medicine | Oncology | Other Oncology | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 50
|
37
|
$ 97
|
70
|
| Percent Change (as a percent) |
36.90%
|
|
39.80%
|
|
| Innovative Medicine | Oncology | Other Oncology | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 42
|
45
|
$ 84
|
86
|
| Percent Change (as a percent) |
(8.70%)
|
|
(2.50%)
|
|
| Innovative Medicine | Immunology |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 3,993
|
4,722
|
$ 7,700
|
8,969
|
| Percent Change (as a percent) |
(15.40%)
|
|
(14.10%)
|
|
| Innovative Medicine | Immunology | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 2,505
|
2,978
|
$ 4,701
|
5,431
|
| Percent Change (as a percent) |
(15.90%)
|
|
(13.40%)
|
|
| Innovative Medicine | Immunology | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,489
|
1,744
|
$ 2,999
|
3,538
|
| Percent Change (as a percent) |
(14.60%)
|
|
(15.20%)
|
|
| Innovative Medicine | Immunology | REMICADE |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 455
|
393
|
$ 922
|
827
|
| Percent Change (as a percent) |
15.90%
|
|
11.50%
|
|
| Innovative Medicine | Immunology | REMICADE | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 283
|
231
|
$ 597
|
497
|
| Percent Change (as a percent) |
22.50%
|
|
20.10%
|
|
| Innovative Medicine | Immunology | REMICADE | U.S. Exports |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 34
|
35
|
$ 44
|
62
|
| Percent Change (as a percent) |
(2.60%)
|
|
(28.70%)
|
|
| Innovative Medicine | Immunology | REMICADE | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 138
|
127
|
$ 281
|
268
|
| Percent Change (as a percent) |
8.60%
|
|
4.80%
|
|
| Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 690
|
537
|
$ 1,349
|
1,091
|
| Percent Change (as a percent) |
28.60%
|
|
23.70%
|
|
| Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 305
|
267
|
$ 597
|
521
|
| Percent Change (as a percent) |
14.00%
|
|
14.40%
|
|
| Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 387
|
270
|
$ 753
|
569
|
| Percent Change (as a percent) |
43.10%
|
|
32.20%
|
|
| Innovative Medicine | Immunology | STELARA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,653
|
2,885
|
$ 3,278
|
5,336
|
| Percent Change (as a percent) |
(42.70%)
|
|
(38.60%)
|
|
| Innovative Medicine | Immunology | STELARA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,078
|
1,855
|
$ 2,059
|
3,251
|
| Percent Change (as a percent) |
(41.90%)
|
|
(36.70%)
|
|
| Innovative Medicine | Immunology | STELARA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 575
|
1,030
|
$ 1,219
|
2,085
|
| Percent Change (as a percent) |
(44.20%)
|
|
(41.50%)
|
|
| Innovative Medicine | Immunology | TREMFYA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,186
|
906
|
$ 2,142
|
1,714
|
| Percent Change (as a percent) |
31.00%
|
|
25.00%
|
|
| Innovative Medicine | Immunology | TREMFYA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 796
|
589
|
$ 1,395
|
1,098
|
| Percent Change (as a percent) |
35.20%
|
|
27.10%
|
|
| Innovative Medicine | Immunology | TREMFYA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 391
|
317
|
$ 747
|
616
|
| Percent Change (as a percent) |
23.20%
|
|
21.20%
|
|
| Innovative Medicine | Immunology | OTHER IMMUNOLOGY |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 8
|
2
|
$ 9
|
2
|
| Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
8
|
2
|
9
|
2
|
| Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 0
|
0
|
$ 0
|
0
|
| Percent Change (as a percent) |
0.00%
|
|
0.00%
|
|
| Innovative Medicine | Infectious Diseases |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 803
|
965
|
$ 1,605
|
1,786
|
| Percent Change (as a percent) |
(16.80%)
|
|
(10.10%)
|
|
| Innovative Medicine | Infectious Diseases | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 320
|
334
|
$ 635
|
658
|
| Percent Change (as a percent) |
(4.30%)
|
|
(3.60%)
|
|
| Innovative Medicine | Infectious Diseases | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 484
|
631
|
$ 971
|
1,128
|
| Percent Change (as a percent) |
(23.40%)
|
|
(13.90%)
|
|
| Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 360
|
297
|
$ 718
|
620
|
| Percent Change (as a percent) |
21.60%
|
|
15.90%
|
|
| Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 6
|
8
|
$ 14
|
16
|
| Percent Change (as a percent) |
(25.40%)
|
|
(13.60%)
|
|
| Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 354
|
288
|
$ 704
|
603
|
| Percent Change (as a percent) |
23.00%
|
|
16.70%
|
|
| Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 396
|
438
|
$ 799
|
856
|
| Percent Change (as a percent) |
(9.40%)
|
|
(6.60%)
|
|
| Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 312
|
321
|
$ 617
|
635
|
| Percent Change (as a percent) |
(3.00%)
|
|
(2.90%)
|
|
| Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 85
|
117
|
$ 183
|
221
|
| Percent Change (as a percent) |
(27.00%)
|
|
(17.20%)
|
|
| Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 47
|
233
|
$ 88
|
311
|
| Percent Change (as a percent) |
(79.80%)
|
|
(71.70%)
|
|
| Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 2
|
5
|
$ 4
|
7
|
| Percent Change (as a percent) |
(51.80%)
|
|
(37.40%)
|
|
| Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 45
|
227
|
$ 84
|
304
|
| Percent Change (as a percent) |
(80.50%)
|
|
(72.50%)
|
|
| Innovative Medicine | Neuroscience |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 2,051
|
1,782
|
$ 3,698
|
3,585
|
| Percent Change (as a percent) |
15.10%
|
|
3.20%
|
|
| Innovative Medicine | Neuroscience | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,377
|
1,102
|
$ 2,345
|
2,156
|
| Percent Change (as a percent) |
24.90%
|
|
8.70%
|
|
| Innovative Medicine | Neuroscience | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 674
|
679
|
$ 1,353
|
1,428
|
| Percent Change (as a percent) |
(0.80%)
|
|
(5.20%)
|
|
| Innovative Medicine | Neuroscience | CAPLYTA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 211
|
0
|
$ 211
|
0
|
| Innovative Medicine | Neuroscience | CAPLYTA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
211
|
0
|
211
|
0
|
| Innovative Medicine | Neuroscience | CAPLYTA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 0
|
0
|
$ 0
|
0
|
| Percent Change (as a percent) |
0.00%
|
|
0.00%
|
|
| Innovative Medicine | Neuroscience | CONCERTA / methylphenidate |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 164
|
163
|
$ 312
|
340
|
| Percent Change (as a percent) |
0.20%
|
|
(8.30%)
|
|
| Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 24
|
34
|
$ 62
|
75
|
| Percent Change (as a percent) |
(27.70%)
|
|
(16.60%)
|
|
| Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 139
|
129
|
$ 249
|
265
|
| Percent Change (as a percent) |
7.50%
|
|
(6.00%)
|
|
| Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 992
|
1,054
|
$ 1,895
|
2,110
|
| Percent Change (as a percent) |
(5.90%)
|
|
(10.20%)
|
|
| Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 732
|
784
|
$ 1,357
|
1,549
|
| Percent Change (as a percent) |
(6.70%)
|
|
(12.40%)
|
|
| Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 260
|
269
|
$ 537
|
561
|
| Percent Change (as a percent) |
(3.50%)
|
|
(4.20%)
|
|
| Innovative Medicine | Neuroscience | SPRAVATO |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 414
|
271
|
$ 734
|
496
|
| Percent Change (as a percent) |
53.30%
|
|
48.10%
|
|
| Innovative Medicine | Neuroscience | SPRAVATO | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 366
|
226
|
$ 642
|
417
|
| Percent Change (as a percent) |
61.10%
|
|
53.70%
|
|
| Innovative Medicine | Neuroscience | SPRAVATO | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 50
|
44
|
$ 93
|
78
|
| Percent Change (as a percent) |
12.80%
|
|
18.10%
|
|
| Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 270
|
294
|
$ 547
|
639
|
| Percent Change (as a percent) |
(8.40%)
|
|
(14.40%)
|
|
| Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 45
|
57
|
$ 73
|
115
|
| Percent Change (as a percent) |
(23.50%)
|
|
(37.00%)
|
|
| Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 226
|
237
|
$ 474
|
524
|
| Percent Change (as a percent) |
(4.70%)
|
|
(9.50%)
|
|
| Innovative Medicine | Pulmonary Hypertension |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,113
|
1,039
|
$ 2,138
|
2,088
|
| Percent Change (as a percent) |
7.10%
|
|
2.40%
|
|
| Innovative Medicine | Pulmonary Hypertension | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 799
|
743
|
$ 1,543
|
1,509
|
| Percent Change (as a percent) |
7.60%
|
|
2.30%
|
|
| Innovative Medicine | Pulmonary Hypertension | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 314
|
296
|
$ 595
|
579
|
| Percent Change (as a percent) |
5.80%
|
|
2.60%
|
|
| Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 582
|
548
|
$ 1,104
|
1,072
|
| Percent Change (as a percent) |
6.40%
|
|
3.00%
|
|
| Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 403
|
376
|
$ 766
|
732
|
| Percent Change (as a percent) |
6.90%
|
|
4.60%
|
|
| Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 180
|
171
|
$ 339
|
340
|
| Percent Change (as a percent) |
5.40%
|
|
(0.30%)
|
|
| Innovative Medicine | Pulmonary Hypertension | UPTRAVI |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 476
|
426
|
$ 927
|
894
|
| Percent Change (as a percent) |
11.70%
|
|
3.70%
|
|
| Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 382
|
349
|
$ 747
|
741
|
| Percent Change (as a percent) |
9.40%
|
|
0.80%
|
|
| Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 94
|
76
|
$ 180
|
152
|
| Percent Change (as a percent) |
22.40%
|
|
17.90%
|
|
| Innovative Medicine | Pulmonary Hypertension | Other |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 55
|
67
|
$ 107
|
123
|
| Percent Change (as a percent) |
(16.90%)
|
|
(12.50%)
|
|
| Innovative Medicine | Pulmonary Hypertension | Other | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 16
|
17
|
$ 31
|
35
|
| Percent Change (as a percent) |
(12.40%)
|
|
(12.60%)
|
|
| Innovative Medicine | Pulmonary Hypertension | Other | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 40
|
49
|
$ 77
|
88
|
| Percent Change (as a percent) |
(18.50%)
|
|
(12.40%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 930
|
892
|
$ 1,943
|
1,721
|
| Percent Change (as a percent) |
4.20%
|
|
12.90%
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 776
|
717
|
$ 1,631
|
1,348
|
| Percent Change (as a percent) |
8.20%
|
|
21.00%
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 154
|
176
|
$ 312
|
373
|
| Percent Change (as a percent) |
(12.30%)
|
|
(16.20%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | Other |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 309
|
305
|
$ 632
|
616
|
| Percent Change (as a percent) |
1.40%
|
|
2.70%
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 155
|
129
|
$ 320
|
243
|
| Percent Change (as a percent) |
20.00%
|
|
31.60%
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 154
|
176
|
$ 312
|
373
|
| Percent Change (as a percent) |
(12.30%)
|
|
(16.20%)
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 621
|
587
|
$ 1,311
|
1,105
|
| Percent Change (as a percent) |
5.60%
|
|
18.60%
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 621
|
587
|
$ 1,311
|
1,105
|
| Percent Change (as a percent) |
5.60%
|
|
18.60%
|
|
| Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 0
|
0
|
$ 0
|
0
|
| Percent Change (as a percent) |
0.00%
|
|
0.00%
|
|
| MEDTECH |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 8,541
|
7,957
|
$ 16,561
|
15,778
|
| Percent Change (as a percent) |
7.30%
|
|
5.00%
|
|
| MEDTECH | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 4,383
|
4,059
|
$ 8,596
|
8,067
|
| Percent Change (as a percent) |
8.00%
|
|
6.60%
|
|
| MEDTECH | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 4,158
|
3,898
|
$ 7,965
|
7,711
|
| Percent Change (as a percent) |
6.70%
|
|
3.30%
|
|
| MEDTECH | Cardiovascular |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 2,313
|
1,873
|
$ 4,416
|
3,679
|
| Percent Change (as a percent) |
23.50%
|
|
20.00%
|
|
| MEDTECH | Cardiovascular | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,364
|
1,119
|
$ 2,625
|
2,144
|
| Percent Change (as a percent) |
21.90%
|
|
22.40%
|
|
| MEDTECH | Cardiovascular | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 948
|
753
|
$ 1,790
|
1,534
|
| Percent Change (as a percent) |
25.90%
|
|
16.70%
|
|
| MEDTECH | ELECTROPHYSIOLOGY |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,468
|
1,323
|
$ 2,791
|
2,667
|
| Percent Change (as a percent) |
11.00%
|
|
4.70%
|
|
| MEDTECH | ELECTROPHYSIOLOGY | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 741
|
705
|
$ 1,425
|
1,397
|
| Percent Change (as a percent) |
5.10%
|
|
2.00%
|
|
| MEDTECH | ELECTROPHYSIOLOGY | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 728
|
618
|
$ 1,366
|
1,270
|
| Percent Change (as a percent) |
17.80%
|
|
7.60%
|
|
| MEDTECH | ABIOMED |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 448
|
379
|
$ 868
|
750
|
| Percent Change (as a percent) |
18.20%
|
|
15.70%
|
|
| MEDTECH | ABIOMED | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 360
|
309
|
$ 699
|
612
|
| Percent Change (as a percent) |
16.60%
|
|
14.20%
|
|
| MEDTECH | ABIOMED | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 89
|
72
|
$ 170
|
139
|
| Percent Change (as a percent) |
25.00%
|
|
22.40%
|
|
| MEDTECH | Shockwave |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 292
|
77
|
$ 550
|
77
|
| MEDTECH | Shockwave | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
233
|
77
|
439
|
77
|
| MEDTECH | Shockwave | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
58
|
0
|
110
|
0
|
| MEDTECH | Other Cardiovascular |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 104
|
93
|
$ 207
|
185
|
| Percent Change (as a percent) |
10.80%
|
|
11.70%
|
|
| MEDTECH | Other Cardiovascular | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 31
|
29
|
$ 63
|
59
|
| Percent Change (as a percent) |
5.40%
|
|
6.30%
|
|
| MEDTECH | Other Cardiovascular | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 72
|
64
|
$ 144
|
126
|
| Percent Change (as a percent) |
13.40%
|
|
14.20%
|
|
| MEDTECH | Orthopaedics |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 2,305
|
2,312
|
$ 4,546
|
4,652
|
| Percent Change (as a percent) |
(0.30%)
|
|
(2.30%)
|
|
| MEDTECH | Orthopaedics | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,420
|
1,422
|
$ 2,804
|
2,870
|
| Percent Change (as a percent) |
(0.20%)
|
|
(2.30%)
|
|
| MEDTECH | Orthopaedics | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 885
|
890
|
$ 1,742
|
1,782
|
| Percent Change (as a percent) |
(0.50%)
|
|
(2.20%)
|
|
| MEDTECH | Orthopaedics | HIPS |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 421
|
417
|
$ 830
|
839
|
| Percent Change (as a percent) |
1.00%
|
|
(1.10%)
|
|
| MEDTECH | Orthopaedics | HIPS | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 271
|
265
|
$ 534
|
535
|
| Percent Change (as a percent) |
2.10%
|
|
(0.20%)
|
|
| MEDTECH | Orthopaedics | HIPS | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 150
|
152
|
$ 296
|
304
|
| Percent Change (as a percent) |
(1.00%)
|
|
(2.50%)
|
|
| MEDTECH | Orthopaedics | KNEES |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 389
|
394
|
$ 778
|
795
|
| Percent Change (as a percent) |
(1.10%)
|
|
(2.00%)
|
|
| MEDTECH | Orthopaedics | KNEES | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 226
|
230
|
$ 457
|
472
|
| Percent Change (as a percent) |
(1.90%)
|
|
(3.10%)
|
|
| MEDTECH | Orthopaedics | KNEES | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 164
|
163
|
$ 322
|
323
|
| Percent Change (as a percent) |
0.00%
|
|
(0.50%)
|
|
| MEDTECH | Orthopaedics | TRAUMA |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 768
|
759
|
$ 1,540
|
1,524
|
| Percent Change (as a percent) |
1.20%
|
|
1.10%
|
|
| MEDTECH | Orthopaedics | TRAUMA | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 501
|
498
|
$ 1,003
|
1,002
|
| Percent Change (as a percent) |
0.70%
|
|
0.10%
|
|
| MEDTECH | Orthopaedics | TRAUMA | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 267
|
260
|
$ 537
|
521
|
| Percent Change (as a percent) |
2.20%
|
|
2.90%
|
|
| MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 727
|
743
|
$ 1,398
|
1,495
|
| Percent Change (as a percent) |
(2.10%)
|
|
(6.50%)
|
|
| MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 422
|
430
|
$ 810
|
862
|
| Percent Change (as a percent) |
(1.70%)
|
|
(6.00%)
|
|
| MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 305
|
314
|
$ 588
|
634
|
| Percent Change (as a percent) |
(2.70%)
|
|
(7.20%)
|
|
| MEDTECH | Surgery |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 2,555
|
2,488
|
$ 4,951
|
4,904
|
| Percent Change (as a percent) |
2.70%
|
|
1.00%
|
|
| MEDTECH | Surgery | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,043
|
995
|
$ 2,045
|
1,982
|
| Percent Change (as a percent) |
4.80%
|
|
3.20%
|
|
| MEDTECH | Surgery | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,512
|
1,493
|
$ 2,906
|
2,922
|
| Percent Change (as a percent) |
1.30%
|
|
(0.50%)
|
|
| MEDTECH | Surgery | ADVANCED |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,164
|
1,141
|
$ 2,237
|
2,228
|
| Percent Change (as a percent) |
2.00%
|
|
0.40%
|
|
| MEDTECH | Surgery | ADVANCED | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 477
|
466
|
$ 934
|
912
|
| Percent Change (as a percent) |
2.20%
|
|
2.40%
|
|
| MEDTECH | Surgery | ADVANCED | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 687
|
675
|
$ 1,303
|
1,316
|
| Percent Change (as a percent) |
1.90%
|
|
(1.00%)
|
|
| MEDTECH | Surgery | GENERAL |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,391
|
1,346
|
$ 2,714
|
2,676
|
| Percent Change (as a percent) |
3.30%
|
|
1.40%
|
|
| MEDTECH | Surgery | GENERAL | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 567
|
528
|
$ 1,111
|
1,070
|
| Percent Change (as a percent) |
7.20%
|
|
3.80%
|
|
| MEDTECH | Surgery | GENERAL | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 825
|
818
|
$ 1,603
|
1,606
|
| Percent Change (as a percent) |
0.90%
|
|
(0.10%)
|
|
| MEDTECH | Vision |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 1,369
|
1,285
|
$ 2,648
|
2,543
|
| Percent Change (as a percent) |
6.50%
|
|
4.10%
|
|
| MEDTECH | Vision | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 557
|
523
|
$ 1,123
|
1,070
|
| Percent Change (as a percent) |
6.50%
|
|
4.90%
|
|
| MEDTECH | Vision | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 813
|
763
|
$ 1,526
|
1,473
|
| Percent Change (as a percent) |
6.50%
|
|
3.60%
|
|
| MEDTECH | Vision | CONTACT LENSES / OTHER |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 965
|
918
|
$ 1,884
|
1,828
|
| Percent Change (as a percent) |
5.10%
|
|
3.10%
|
|
| MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 429
|
409
|
$ 881
|
847
|
| Percent Change (as a percent) |
4.80%
|
|
3.90%
|
|
| MEDTECH | Vision | CONTACT LENSES / OTHER | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 536
|
509
|
$ 1,003
|
981
|
| Percent Change (as a percent) |
5.40%
|
|
2.30%
|
|
| MEDTECH | Vision | SURGICAL |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 403
|
367
|
$ 764
|
715
|
| Percent Change (as a percent) |
9.90%
|
|
6.90%
|
|
| MEDTECH | Vision | SURGICAL | U.S. |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 128
|
113
|
$ 242
|
223
|
| Percent Change (as a percent) |
12.60%
|
|
8.50%
|
|
| MEDTECH | Vision | SURGICAL | International |
|
|
|
|
| Sales by segment of business |
|
|
|
|
| Sales to customers |
$ 277
|
$ 254
|
$ 523
|
$ 492
|
| Percent Change (as a percent) |
8.80%
|
|
6.20%
|
|